Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 9/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.39 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.39 |
| ▸ | BRAF | P15056 | 2/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | UBE2N | P61088 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HCK | P08631 | 3/20 | 0.38 |
| ▸ | NR2C2 | P49116 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | INSR | P06213 | 2/20 | 0.37 |
| ▸ | LCK | P06239 | 2/20 | 0.37 |
| ▸ | LYN | P07948 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13291968 | 0.86 | CSF1R (0.57) | CSF1RDDR2BRAFHCKNR2C2 | |
| SCHEMBL17470233 | 0.85 | ATM (0.56) | CSF1RATMMAPTKMT2ANPSR1 | |
| SCHEMBL13291961 | 0.84 | MAPT (0.51) | MAPTKDM4EPOLBBRAFRAF1 | |
| SCHEMBL22688599 | 0.83 | ATM (0.45) | ATMMAPTKMT2ANPSR1KDM4E | |
| SCHEMBL1828842 | 0.82 | KDM4E (0.39) | CSF1RMAPTKDM4EPOLBDDR1 | |
| SCHEMBL3233580 | 0.82 | BRAF (0.49) | ATMMAPTDDR1BRAFHCK | |
| SCHEMBL13301729 | 0.80 | HCK (0.42) | MAPTKMT2AKDM4EPOLBBRAF | |
| SCHEMBL1822577 | 0.79 | LYN (0.51) | CSF1RBRAFHCKINSRLCK | |
| SCHEMBL3234488 | 0.79 | CSF1R (0.60) | CSF1RATMDDR2BRAFHCK | |
| SCHEMBL1824003 | 0.77 | INSR (0.60) | CSF1RBRAFRAF1HCKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758892-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2012-10-17 | — | — | EP | claimed |
| JP-4688876-B2 | — | — | 2011-05-25 | — | — | JP | claimed |
| US-7745437-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-06-29 | — | — | US | claimed |
| US-20070225286-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2007-09-27 | — | — | US | claimed |
| EP-1758892-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-03-07 | — | — | EP | claimed |
| WO-2005123719-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-12-29 | — | — | WO | claimed |
| US-20160082015-A1 | METHODS, COMPOSITIONS AND KITS FOR PROMOTING MOTOR NEURON SURVIVAL AND TREATING AND DIAGNOSING NEURODEGENERATIVE DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-24 | — | — | US | disclosed |
| EP-1758892-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2012-10-17 | — | — | EP | disclosed |
| EP-1758892-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2012-10-17 | — | — | EP | disclosed |
| US-7745437-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-06-29 | — | — | US | disclosed |
| US-7745437-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-06-29 | — | — | US | disclosed |
| US-7745437-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-06-29 | — | — | US | disclosed |
| US-20070225286-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2007-09-27 | — | — | US | disclosed |
| EP-1758892-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123719-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160082015-A1 | METHODS, COMPOSITIONS AND KITS FOR PROMOTING MOTOR NEURON SURVIVAL AND TREATING AND DIAGNOSING NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SOD1, NEFM | CSF1R 3226/4885ATM 1995/4885MAPT 35/4885 |
| US-20070225286-A1 | Compounds and Compositions as Protein Kinase Inhibitors | BMX, PTK2B, SRC | CSF1R 1032/4885ATM 848/4885MAPT 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.